ArticleCase reports in nephrology and dialysis
Efficacy of Belimumab for Active Lupus Nephritis in a Young Asian Man with Latent Pulmonary Tuberculosis: A Case Report.
Article in Case reports in nephrology and dialysis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Managing active lupus nephritis (LN) in the presence of latent tuberculosis (TB) presents a significant treatment challenge. Traditional treatment with glucocorticoids combined with mycophenolic acid carries a high risk of triggering pulmonary TB infection in LN patients. In this report, we discuss a novel approach using belimumab in combination with rapidly tapering corticosteroids to treat a patient with active class IV and V LN and latent TB. Case Presentation: A 24-year-old Chinese male was diagnosed with active class IV and V LN and latent TB. He underwent induction therapy with a combination of belimumab, rapidly tapering methylprednisolone and mycophenolate mofetil. After 18 months of belimumab therapy, the patient's blood albumin levels and kidney function normalized, with 24-h urinary protein levels stabilizing between 500 mg and 725 mg. Notably, there was no recurrence of TB. Conclusion: This case demonstrates that the combination of belimumab and rapid corticosteroid tapering effectively reduced the duration of high-dose glucocorticoid therapy, highlighting the efficacy and safety of belimumab in managing LN with latent TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.